Pharma Focus America
ThermoFisherScientific - Custom and Bulks

LATEST NEWSRead more...

12

Jun 2024

Eilean Therapeutics Partners with the Leukemia & Lymphoma Society for the Beat AML® Master Clinical Trial

Eilean Therapeutics AU Pty Ltd a biopharmaceutical firm committed to developing advanced small molecule inhibitors for hematologic and solid cancers has partnered with The Leukemia Lymphoma Society

12

Jun 2024

Myriad Genetics and GSK Team Up to Broaden Access to HRD Testing in Nine Countries

Myriad Genetics Inc a leader in genetic testing and precision medicine has announced a partnership with GSK to improve access to homologous recombination deficiency diagnostic testing for patients

12

Jun 2024

InnoCare Receives FDA Clearance for Clinical Trial of TYK2 Inhibitor ICP-332

InnoCare Pharma a leading biopharmaceutical company focused on treatments for cancer and autoimmune disorders has received approval from the US Food and Drug Administration for the Investigational New Drug application for its new TYK

11

Jun 2024

Shattuck Labs Receives FDA Orphan Drug Status for SL-172154 Targeting Acute Myeloid Leukemia (AML)

Shattuck Labs Inc a clinicalstage biotechnology firm developing innovative bifunctional fusion proteins for cancer and autoimmune treatments has announced that the FDA

11

Jun 2024

Calidi Biotherapeutics Collaborates with SIGA Technologies to Develop RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi Biotherapeutics Inc a biotechnology firm focused on clinicalstage research is developing the RTNova virotherapy platform aimed at creating innovative cancer treatments

11

Jun 2024

TAGRISSO® (Osimertinib) Granted Priority Review for Stage III EGFR-Mutated Lung Cancer Treatment in the US

AstraZeneca has submitted a supplemental New Drug Application for TAGRISSO which has been accepted for Priority Review by the FDA This application seeks approval for TAGRISSO

press releasesRead more...

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma Inc a late clinicalstage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration

Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Regeneron Pharmaceuticals Inc and Sanofi today announced that the US Food and Drug Administration has approved Kevzara for the treatment of patients weighing kg or greater with active polyarticular juvenile idiopathic arthritis

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Repare Therapeutics Inc a leading clinicalstage precision oncology company today announced the first patient has been dosed in the Companys camonsertib

US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

GSK plc today announced that the US Food and Drug Administration has approved AREXVY for the prevention of RSV lower respiratory tract disease

11 - 13

Jun 2024

13 - 14

Jun 2024

13 - 14

Jun 2024

13 - 14

Jun 2024

14 - 17

Jun 2024

18 - 19

Jun 2024

5th RNA Editing Summit

Boston, MA, USA

18 - 19

Jun 2024

18 - 20

Jun 2024
Testing The WorldCelebrating 70 Years of Nalgene
Thermo Fisher Scientific viral vector services (VVS)
Future Labs Live USA 2024
patheon - Mastering API production at every scale
World Orphan Drug Congress Europe 2024

TOP ARTICLES

  • 1

    Understanding Over-the-Counter (OTC) Drugs: Trends and Opportunities in Pharma

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

  • 2

    Navigating the Storm: Emerging Challenges in the Pharmaceutical Industry

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

  • 3

    Pharmacovigilance in the Age of AI: Enhancing Drug Safety with Technology

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

  • 4

    Biomarkers in Focus: Enhancing Clinical Research and Patient Care

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

  • 5

    The Future of Quality Control: ML Applications in Pharmaceuticals

    Kate Williamson

    Kate, Editorial Team at Pharma Focus America, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

KNOWLEDGE BANK

EDITORIAL SECTION

  • Information Technology

    How AI is Transforming the Pharma Industry

    The global pharmaceutical industry is currently facing many wide ranging challenges including an aging population increased life expectancy a rise in chronic conditions reduced funding for treatments reduced numbers of clinical staff the ever increasing cost of drug development and raw materials and supply chain issues